PSTV

Plus Therapeutics, Inc. [PSTV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PSTV Stock Summary

Top 10 Correlated ETFs

PSTV


Top 10 Correlated Stocks

PSTV


In the News

10:05 10 Dec 2023 PSTV

Penny Stocks To Buy Now? 4 To Watch Before Next Week

Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth and upside.

07:46 10 Dec 2023 PSTV

Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.

09:21 10 Dec 2023 PSTV

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting

04:05 10 Dec 2023 PSTV

Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023

AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

07:00 10 Dec 2023 PSTV

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM) .

07:00 10 Dec 2023 PSTV

Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 3:00 p.m. ET at the Lotte New York Palace in New York, NY.

09:52 10 Dec 2023 PSTV

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capita Operator Good afternoon, ladies and gentlemen.

04:05 10 Dec 2023 PSTV

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

07:00 10 Dec 2023 PSTV

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m. ET at the InterContinental Boston in Boston, Mass.

07:00 10 Dec 2023 PSTV

Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.

PSTV Financial details

Company Rating
Buy
Market Cap
9.59M
Income
-15.25M
Revenue
2.08M
Book val./share
0.81
Cash/share
3.41
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
21 Feb 2024
P/E
-0.45
Forward P/E
-0.85
PEG
0.07
P/S
4.61
P/B
2.61
P/C
0.62
P/FCF
-0.72
Quick Ratio
1.05
Current Ratio
1.1
Debt / Equity
1.75
LT Debt / Equity
0.05
-
-
EPS (TTM)
-6.22
EPS next Y
-2.5
EPS next Q
-1.26
EPS this Y
-33.01%
EPS next Y
-59.86%
EPS next 5Y
-79.34%
EPS last 5Y
-59.48%
Revenue last 5Y
-40.42%
Revenue Q/Q
-
EPS Q/Q
69.49%
-
-
-
-
SMA20
29.93%
SMA50
51.59%
SMA100
-11.57%
Inst Own
5.79%
Inst Trans
0.55%
ROA
-115%
ROE
-424%
ROC
-5.49%
Gross Margin
100%
Oper. Margin
-723%
Profit Margin
-734%
Payout
-
Shs Outstand
4.52M
Shs Float
4.42M
-
-
-
-
Target Price
-
52W Range
0.97-7.2
52W High
-
52W Low
-
RSI
59.55
Rel Volume
0.07
Avg Volume
612.86K
Volume
44.65K
Perf Week
24.71%
Perf Month
96.3%
Perf Quarter
-30.26%
Perf Half Y
-41.6%
-
-
-
-
Beta
0.632
-
-
Volatility
0.17%, 0.33%
Prev Close
-4.93%
Price
2.12
Change
4.95%

PSTV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
257.3875.851.0300.13
Net income per share
-1.09K-138.1-31.67-17.78-11.91
Operating cash flow per share
-1.03K-64.01-28.57-12.76-7.41
Free cash flow per share
-1.04K-64.74-30.24-12.93-7.7
Cash per share
453.93190.2328.2722.8310.35
Book value per share
450.8212.5710.2713.453.68
Tangible book value per share
-95.258.548.7212.923.42
Share holders equity per share
450.8212.5710.2713.453.68
Interest debt per share
1.39K148.5727.459.833.63
Market cap
2.52M3.32M8.94M12.69M8.4M
Enterprise value
11.46M-2.38M7.59M1.29M-4.07M
P/E ratio
-0.2-0.26-0.96-0.89-0.4
Price to sales ratio
0.850.4729.52037.51
POCF ratio
-0.21-0.56-1.06-1.23-0.65
PFCF ratio
-0.21-0.56-1-1.22-0.62
P/B Ratio
0.482.862.951.171.3
PTB ratio
0.482.862.951.171.3
EV to sales
3.84-0.3425.060-18.18
Enterprise value over EBITDA
-1.710.88-0.83-0.110.21
EV to operating cash flow
-0.960.4-0.9-0.130.31
EV to free cash flow
-0.950.4-0.85-0.120.3
Earnings yield
-5.01-3.84-1.05-1.13-2.48
Free cash flow yield
-4.8-1.8-1-0.82-1.6
Debt to equity
2.7210.222.310.650.88
Debt to assets
0.590.510.580.320.24
Net debt to EBITDA
-1.332.110.150.950.66
Current ratio
0.551.371.073.361.84
Interest coverage
-4.56-1.97-8.66-13.4-27.72
Income quality
0.950.541.020.770.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.870.6921.14045.71
Research and developement to revenue
1.850.7711.49043.29
Intangibles to total assets
0.020.020.040.020.02
Capex to operating cash flow
0.010.010.060.010.04
Capex to revenue
-0.04-0.01-1.630-2.27
Capex to depreciation
-0.07-0.07-1.35-0.36-0.82
Stock based compensation to revenue
0.120.020.8202.71
Graham number
3.33K197.6585.5373.3431.41
ROIC
-0.55-1.03-1.02-0.73-1.64
Return on tangible assets
-0.53-0.56-0.8-0.66-0.89
Graham Net
-1.15K-38.87-2.3290.4
Working capital
-7.91M5.34M636K13.85M9.97M
Tangible asset value
4.85M788K2.57M10.41M5.98M
Net current asset value
-9.12M-2.24M101K8.58M4.4M
Invested capital
2.7210.222.310.650.88
Average receivables
189K701K614K33K3.5K
Average payables
1.01M524K558K1.7M5.49M
Average inventory
1.65M107K53.5K-3.5K-3.5K
Days sales outstanding
28.5160.9771.0700
Days payables outstanding
229.240014.44K0
Days of inventory on hand
34.0200-38.710
Receivables turnover
12.85.995.1400
Payables turnover
1.59000.030
Inventory turnover
10.7300-9.430
ROE
-2.42-10.98-3.08-1.32-3.23
Capex per share
-11.48-0.73-1.67-0.18-0.29

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.100.740
Net income per share
-2.92-2.56-2.07-0.59-1
Operating cash flow per share
-2.31-1-2.5-1.11-0.74
Free cash flow per share
-2.33-1-2.54-1.11-0.75
Cash per share
11.088.085.484.343.41
Book value per share
6.232.871.151.060.81
Tangible book value per share
5.972.660.960.890.68
Share holders equity per share
6.232.871.151.060.81
Interest debt per share
3.372.592.362.021.45
Market cap
12.35M10.77M10.09M5.07M4.32M
Enterprise value
-1.92M-1.71M2.7M-871.06K-2.1M
P/E ratio
-0.58-0.47-0.52-0.86-0.34
Price to sales ratio
048.0802.730
POCF ratio
-2.92-4.82-1.74-1.82-1.8
PFCF ratio
-2.9-4.8-1.71-1.82-1.79
P/B Ratio
1.081.673.771.91.65
PTB ratio
1.081.673.771.91.65
EV to sales
0-7.620-0.470
Enterprise value over EBITDA
0.390.32-0.60.70.73
EV to operating cash flow
0.460.76-0.470.310.88
EV to free cash flow
0.450.76-0.460.310.87
Earnings yield
-0.43-0.53-0.48-0.29-0.74
Free cash flow yield
-0.34-0.21-0.58-0.55-0.56
Debt to equity
0.530.881.991.861.75
Debt to assets
0.260.240.340.350.35
Net debt to EBITDA
2.922.341.654.792.22
Current ratio
2.811.841.071.081.1
Interest coverage
-29.45-35.04-35.22-13.3-37.37
Income quality
0.810.391.211.870.75
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
01601.040
Research and developement to revenue
09.5400.770
Intangibles to total assets
0.020.020.030.030.03
Capex to operating cash flow
0.0100.0200
Capex to revenue
0-0.050-0.010
Capex to depreciation
-0.21-0.07-0.52-0.08-0.04
Stock based compensation to revenue
00.5800.080
Graham number
20.2412.867.333.754.27
ROIC
-0.3-0.46-0.57-0.2-0.45
Return on tangible assets
-0.24-0.25-0.32-0.11-0.25
Graham Net
4.710.31-0.1-0.040.13
Working capital
13.46M9.97M833K965K1.05M
Tangible asset value
10.92M5.98M2.23M2.23M2.2M
Net current asset value
9.18M4.4M667K829K928K
Invested capital
0.530.881.991.861.75
Average receivables
36.5K36.5K0359K404.5K
Average payables
5.48M7.03M7.43M3.25M0
Average inventory
00000
Days sales outstanding
00034.850
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0002.580
Payables turnover
00000
Inventory turnover
00000
ROE
-0.47-0.89-1.8-0.56-1.23
Capex per share
-0.020-0.0400

PSTV Frequently Asked Questions

What is Plus Therapeutics, Inc. stock symbol ?

Plus Therapeutics, Inc. is a US stock , located in Austin of Tx and trading under the symbol PSTV

What is Plus Therapeutics, Inc. stock quote today ?

Plus Therapeutics, Inc. stock price is $2.12 today.

Is Plus Therapeutics, Inc. stock public?

Yes, Plus Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Similar Market Cap